Managing arthritis and vascular disease -a rheumatology perspective
In patients who have hypertension that is difficult to control, or poor cardiac function or poor renal function (estimated glomerular filtration rate less than 60 mL/min/1.73 m 2 ), or some combination thereof, it is best to avoid use of NSAIDs. The pharmacological actions of NSAIDs militate against effective management of these problems. Usually an alternative treatment for arthritis is available.
Osteoarthritis is the most prevalent form of arthritis and is increasingly common with advancing years. NSAIDs are used in osteoarthritis for symptomatic relief but have not been shown to retard the anatomical progression to joint failure. Recognising that the usefulness of NSAIDs is limited to analgesic effects helps dampen the enthusiasm of patients for their use, especially when coupled with warnings about the serious and potentially life-threatening adverse effects.
These include upper gastrointestinal events and the increased risk of thrombotic cardiovascular events. The risk of these complications is likely to be influenced by an NSAID's halflife and selectivity for the isoforms of cyclo-oxygenase (COX).
Drugs with a higher selectivity for COX-2 have a greater risk of cardiovascular adverse events.
The practical limitations of NSAIDs in osteoarthritis help redirect the prescriber to other analgesic options. Paracetamol is the recommended first-line analgesic. Narcotic analgesics may be useful for severe osteoarthritic pain in patients whose cardiac and renal function is compromised. The non-pharmacological therapies for osteoarthritis should not be overlooked. Exercise prescriptions can improve comfort and well-being. The focus needs to be on local exercises, that address muscle imbalances and improve or maintain the range of movement, and more general exercises that improve overall fitness without local aggravation. When indicated, and feasible from a cardiovascular viewpoint, joint replacement surgery can relieve pain, improve function and allow better overall fitness to be achieved.
Improved cardiorespiratory fitness and an associated reduction in adiposity can aid blood pressure control. The natural products glucosamine and chondroitin sulfate may reduce symptoms in osteoarthritis and do not appear to compromise blood pressure control or the treatment of heart failure. 1 In rheumatoid arthritis, NSAIDs are no longer regarded as first-line treatment, except in the sense that they are used to lessen symptoms before starting a disease-modifying anti-inflammatory drug. These drugs include methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, gold sodium thiomalate, cyclosporin and anticytokine 'biological' therapies.
The best results are achieved with early implementation of combination therapy with three or more drugs. 2 Glucocorticoids For many children their first encounter with the health system is a painful one. As poorly managed pain in childhood can lead to later avoidance of healthcare, John Murtagh tells us how to minimise the pain of procedures, including immunisation.
The immune system is the target of the new immunosuppressants discussed by Peter Pillans and Paul
Trevillian. Immunosuppressants are among the drugs that Fin Zheng Jun Cai, Les Cleland and Michael James say are more appropriate than non-steroidal anti-inflammatory drugs in the early stages of rheumatoid arthritis.
Cancer treatments can affect the immune system, but they have other unpleasant adverse effects such as xerostomia which is reviewed by Ian Olver.
are enjoying a second vogue as a means of controlling symptoms quickly during the period between starting and responding to a disease-modifying drug. The long-term use of glucocorticoids needs to be weighed against their serious adverse effects, such as their propensity to cause hypertension.
When prescribing combination therapy for rheumatoid arthritis, it is important to make dosage adjustments and substitutions in order to achieve objective evidence of disease suppression and to accommodate intolerance to individual drugs or drug-related adverse events. Disease control is of paramount importance in order to reduce cumulative joint damage and the increased cardiovascular mortality 3 , both of which have been shown to correlate with unsuppressed disease activity.
There is evidence that fish oil in anti-inflammatory doses can reduce symptoms in rheumatoid arthritis 4 and that fish oil (and other interventions which increase dietary intake of omega-3 fatty acids) generally reduces cardiovascular mortality. 5 Fish oil has also been shown to reduce discretionary NSAID use in rheumatoid arthritis. 4 It also has a number of favourable effects on cardiovascular physiology, including a modest reduction in blood pressure and reduced arterial stiffness.
The important practical point is that a 'need' for NSAIDs in rheumatoid arthritis can be used as a prompt for more intensive application of other therapies. This approach is especially important in patients for whom treatment of other health problems, such as hypertension and heart failure, may be compromised by NSAIDs.
Situations do arise in which it is decided that a patient with cardiovascular disease requires treatment with an NSAID when alternative approaches have failed. If possible the NSAID should be used for second-line analgesia in as small a dose and for as short a period as needed to control symptoms. 6 
Pre-eclampsia
Editor, -I read with interest the article on biochemical tests in pregnancy (Aust Prescr 2006;29:48-52) and wish to comment on the discussion of pre-eclampsia. The author maintains that the diagnosis is based on a triad of hypertension, proteinuria and oedema, yet the Australasian Society for the Study of Hypertension in Pregnancy has issued a consensus statement which asserts otherwise. 1 While hypertension is a requirement, proteinuria (as one of a range of possible end organ effects) is not mandatory to make the diagnosis. Oedema is specifically excluded unless its onset is rapid and generalised. This is important to appreciate as severe forms of pre-eclampsia (and indeed eclampsia) can occur in the absence of the 'triad'.
Furthermore, 'routine' urinalysis at each visit in low-risk pregnancies has been discontinued in many centres due to its limited value. In pre-eclampsia the detection of hypertension is of utmost importance and blood pressure needs to be rigorously controlled. The presence of proteinuria and oedema is less critical but will further assist in arriving at the correct diagnosis. Although eclampsia can occur in the absence of the 'triad', alternative differential neurological diagnoses need to be considered.
While the clinical utility of 'routine' urinalysis may not be as important in the diagnosis of pre-eclampsia, it is sometimes useful in detecting asymptomatic bacteriuria and glycosuria.
Bacteriuria confers an increased risk of pyelonephritis and prematurity 1 , and glycosuria may identify unsuspected diabetes other than gestational diabetes. Interventions for both of these conditions can result in better outcomes. 1, 2 It is of additional interest that the current British guideline for antenatal care recommends that 'whenever blood pressure is measured in pregnancy a urine sample should be tested at the same time for proteinuria'. 3 The decision to discontinue this practice in low-risk patients is then probably a function of cost versus benefit. These drugs should only be given in conjunction with bladder training at the lowest dose possible to achieve reduced frequency, urgency or urge incontinence, and for the shortest duration possible. 
Deleterious cognitive effects of antimuscarinic drugs

Confessions of a biased reader
Managing painful paediatric procedures Introduction
The treatment of painful procedures in children requires special consideration and planning because pain preventive measures reduce both short-term and long-term morbidity.
Current evidence indicates that pain and distress in children is poorly managed and children continue to suffer unnecessarily. 1 This can lead to anticipatory anxiety, needle phobia and the avoidance of health care. Obviously, it is impossible to make many basic procedures such as immunisation and other injections painless, but there are strategies to minimise the pain.
Before inflicting pain on a child always consider if the procedure is justified.
General distracting and rapport-building techniques
The strategies used will depend on the age of the child and the support of the parents. injection is to get the child to take a deep breath followed by a series of rapid blowing, during which the injection is given. 3
Wound repair
Wherever possible it is worth using a simple painless technique without compromising good healing.
Scalp lacerations
If lacerations are small but gaping, use the child's hair to tie the wound together. This, of course, only applies to children with long hair. Do not use this method for large wounds.
Method
■ make a twisted bunch of the child's own hair of appropriate size on either side of the wound ■ tie a reef knot across the wound and then an extra holding knot to minimise slipping ■ as you tie, ask an assistant to drip compound benzoin tincture solution (friar's balsam) or plastic skin on the hair knot ■ as this congeals, the knot is further consolidated against slipping.
Leave the tied hair long. The parents can cut the knot about five days later when the wound has healed. The whole procedure is painless unless an injection of tetanus toxoid is indicated.
Reinforced paper adhesive strips (for example, steri-strips)
These strips should be used only for very superficial epidermal wounds or in conjunction with sutures. Despite the temptation, avoid using them in children with open wounds, especially on the forehead. They will merely close the dermis and cause a thin, stretched scar.
Skin glues -an alternative to sutures
Cyanoacrylate tissue adhesives are available for wound closure.
These glues act by polymerising with the thin water layer on the skin's surface to form a bond.
Precautions (see box)
The glue should be used only for superficial, dry, clean and fresh skin wounds. It must not be applied for deep wounds or wounds under excessive tension. Contact with the cornea or conjunctiva must be avoided, as this can cause adhesions. It is important that the wound is clean and dry and the wound edges are precisely opposed. No gaps are permissible with the glue method of wound repair.
Wound anaesthesia
There are several methods of achieving relative or absolute anaesthesia of wounds for suturing or debridement. The more important less painful strategies include the use of topical anaesthetic drugs and wound infiltration.
Topical local anaesthesia
Topical anaesthetic drugs that can be used for instilling in minor wounds in children are listed in 
Method of use 4
■ thoroughly clean the wound (should be less than 5 cm) ■ use LAT or ALA in a dose 0.1 mL/kg bodyweight ■ apply this solution on a piece of gauze or cotton wool placed inside the wound and hold in place with an adhesive clear plastic dressing ■ leave for 20-30 minutes (an area of blanching about 1 cm wide will appear around the wound).
Anaesthesia is obtained about 20 to 30 minutes after instillation.
Test the adequacy of anaesthesia by washing and squeezing the wound or prodding it with forceps -if this is pain-free, suturing will usually be painless.
Improvised topical 'anaesthesia'
It is worth considering the use of a block of ice to chill the lacerated site in children. The child or parent is asked to hold the ice then lift it while a suture is rapidly inserted. Another variation that is especially useful in older children is to use a vapocoolant spray on the skin where anaesthesia is required, such as incising a small abscess.
Injectable local anaesthetic
Injectable lignocaine 1% can be used: 
Immunisation
Controversy surrounds the optimal method of mass immunisation involving intramuscular injections. An Australian study showed that fewer adverse effects, in terms of irritability and local reactions, resulted from the gluteal approach compared with the anterolateral thigh approach. 5 The Australian
Immunisation Handbook does not recommend the gluteal approach because of the theoretical risk of sciatic nerve damage.
However, this method is officially recommended in countries such as Japan and Croatia and is widely used in Belgium, Germany, Italy and Denmark.
The World Health Organization (WHO) advises an anterolateral thigh injection with a 25 gauge/16 mm needle inserted at 90° to the skin, while the Australian and USA techniques use a longer and larger bore 23 gauge/25 mm needle inserted at 45° and 60° respectively. The Australian study found that the WHO method 'appears to be the optimal technique for anterolateral thigh injection in children -it ensures that the injection is intramuscular, results in fewer adverse reactions, and is the easiest technique to perform as it does not require angling of the needle to the long axis of the femur'. 6 However, the Australian Immunisation Handbook continues to recommend a 23 gauge/25 mm needle inserted at 45°.
The use of topical drugs such as EMLA has been shown to reduce pain scores in infants receiving immunisation. However, the slow onset and the need to inject into several sites at once may make this approach impractical.
Other procedures
Consider the following strategies for painful and distressing procedures such as venepuncture, intravenous cannulation and lumbar puncture:
■ distracting and relaxation skills ■ pacifier with 15-50% sucrose in infants up to 3 months ■ swaddling and containment of infants ■ topical anaesthetic drugs such as EMLA cream or AnGel applied at the recommended time before needling.
There is evidence to suggest that using topical anaesthesia does not make cannulation more difficult. A painless procedure may be more successful than a painful one. 7 More painful procedures will require the use of sedation 
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Self-test questions
The following statements are either true or false (answers on page 115)
1. Neonates exposed to painful procedures may later develop neurobehavioural dysfunction.
2. The use of topical anaesthesia before an injection of local anaesthetic is contraindicated.
Xerostomia: a common adverse effect of drugs and radiation
Ian N Olver, Chief Executive Officer, The Cancer Council Australia, Sydney Summary Xerostomia is the subjective sensation of dry mouth. Many drugs, especially those with anticholinergic effects, can cause xerostomia, particularly in the elderly. Another major cause is radiotherapy to the head and neck damaging the salivary glands. Newer techniques to target radiotherapy and protective drugs, such as amifostine, could decrease the incidence of xerostomia. Treatment is based on either stimulating the flow of remaining salivary tissue with lollies or sialogogues such as pilocarpine, or wetting the mucosa with water or artificial saliva containing glycerine or compounds such as carboxymethylcellulose. Patients need regular dental examinations because of the effect of xerostomia on intra-oral health.
Key words: pilocarpine, radiotherapy, salivary glands, sialogogues.
(Aust Prescr 2006;29:97-8)
Introduction
Xerostomia is the subjective feeling of having a dry mouth.
It is associated with dysfunction of the salivary glands. These Not only is lubrication a necessary part of chewing food prior to swallowing, but saliva impacts on the oral microbial environment, the maintenance of the oral immune system and also the mineralisation of teeth. The initial volume, particularly of the parotid glands, will also affect the degree of xerostomia post-radiation. If only one side is irradiated some recovery will occur over the following year as a result of compensatory hypertrophy of the remaining glands.
Causes
Symptoms
The most frequent symptoms of xerostomia are the need to keep the mouth moist with water, particularly at night, and difficulty with speech. There is also a loss of taste and difficulty chewing and swallowing dry foods. This can in turn cause loss of appetite and weight. Patients find it difficult to tolerate dental prostheses and are more prone to dental caries. Burning and tingling sensations on the tongue are reported. Fissuring of the lips and mouth ulcers increase the chance of secondary fungal infections in the mouth. 
Evaluation
Prevention
General nutrition and hydration are important to help reduce the severity of xerostomia. Avoiding or decreasing the doses of the many drugs which are associated with xerostomia, particularly in the elderly, is a useful precaution.
Patients are encouraged to regularly practice oral and dental hygiene, and if they wear dentures, not to leave them in at night. They should avoid sugary or acidic foods or irritating spicy foods. 3 Stopping alcohol and smoking will help to decrease dental disease.
Pre-radiation
Before radiotherapy, patients should be reviewed by a dentist and have any necessary dental treatment, for example the application of fluoride gels. Antifungal drugs may be used to prevent candidiasis in patients at high risk of infection.
Another major strategy to try to prevent xerostomia is to better target the radiotherapy. Newer techniques including threedimensional planning and intensity-modulated radiation, where the dosage can be varied across the treatment volume, aim to spare the normal tissues including the salivary glands. In very specific cases, such as a head and neck cancer with no neck nodes involved where only one side of the neck is being irradiated, a submandibular gland can be surgically transferred to a shielded area in the submental space to protect it from the radiation.
Drugs are being developed to try to protect normal tissues from chemotherapy or radiation damage. Amifostine, a thiol free radical scavenger, has been shown to reduce the damage to salivary glands when given concomitantly with radiation such as radioiodine for treating the thyroid gland. The adverse effects of amifostine include nausea and hypotension and it needs to be injected daily. 4
Treatment
The initial strategy to treat xerostomia is to try to stimulate any remaining salivary gland tissue. This may be achieved by chewing gum or by sucking sugarless lollies.
Sialogogues are drugs which stimulate saliva production. They are essentially muscarinic-cholinergic analogues which act on smooth muscle and exocrine glands. Pilocarpine can increase salivary flow after radiotherapy, but is associated with adverse effects such as perspiration, flushing and increased bowel and bladder motility. 5 
Introduction
Immunosuppressants are essential for successful organ transplantation and the treatment of many autoimmune disorders. They suppress rejection and dampen the autoimmune process, but they also lead to the undesired consequences of immunodeficiency, such as infection or malignancy, and non-immune toxicity. 1 Glucocorticoids and thiopurines such as azathioprine are still widely used, but newer potent drugs have become the cornerstone of many treatments.
Azathioprine
Azathioprine is a prodrug which is converted to 
Calcineurin inhibitors
Calcineurin catalyses some of the intracellular processes associated with the activation of T-lymphocytes. When calcineurin inhibitors bind to intracellular proteins called immunophilins, they block the effect of calcineurin. This results in reduced production of interleukin-2 and reduced proliferation of T-cells.
The nephrotoxicity of calcineurin inhibitors has emerged as an increasing cause of late renal allograft loss. The pathogenesis appears to be multifactorial and includes calcineurin-induced vasoconstriction, calcineurin-induced release of endothelin-1 (a potent vasoconstrictor), decreased production of the vasodilator nitric oxide, and increased expression of transforming growth factor beta 1 (a key cytokine associated with interstitial fibrosis). 3 Reducing the dose of calcineurin inhibitor, or using protocols including mycophenolate and sirolimus, may minimise the risk of nephrotoxicity and improve allograft and patient survival.
Cyclosporin
Since the early 1980s, cyclosporin has been the primary immunosuppressant used in transplantation. It binds with cyclophilin to inhibit calcineurin. 
Antiproliferative drugs
Sirolimus (rapamycin) and everolimus are structurally very similar and have the same mechanism of action. Like tacrolimus, they bind to FK-binding protein, but they have no effect on calcineurin. Instead, the complex inhibits a protein kinase that is critical for cell cycle progression. This kinase is known as the mammalian target of rapamycin (mTOR).
Inhibition of mTOR suppresses cytokine driven T-lymphocyte
proliferation and activation, resulting in immunosuppression.
The main difference between sirolimus and everolimus is that 
Immunosuppressant antibodies
Antithymocyte globulin
This is a polyclonal IgG antibody from horses or rabbits 
Muromonab-CD3
This is a mouse-derived monoclonal antibody which binds to the CD3 component of the T-cell receptor complex leading to T-cell depletion. Muromonab is also associated with the cytokine release syndrome which can range from a mild self-limiting flu-like illness to more serious manifestations including pulmonary oedema and neuropsychiatric adverse reactions.
Neutralising antibodies can develop which block the effect and limit the re-use of muromonab-CD3. A longer-term concern is the increased incidence of lymphoma.
Conclusion
Advances in transplantation and the treatment of 
Self-test questions
The following statements are either true or false if there is clinical concern.) In the withdrawal phase, non-specific polyarthralgias and myalgias are common, but generally respond to a small dose increment followed by a renewed, slower taper.
Second-line drugs, usually antiproliferative drugs such as azathioprine, mycophenolate or methotrexate, may have a steroid-sparing effect in the maintenance phase of treatment.
However, they also have their own toxicities.
Patients prescribed corticosteroids should be told to expect the common early adverse effects, such as sweatiness, hoarse voice, loss of diurnal sleep patterns, and appetite stimulation.
Rarely, more serious acute psychiatric disturbances are seen such as agitation, aggression or psychosis. Long-term, and less reversible, adverse effects include Cushingoid appearance, proximal myopathy, hypertension, hyperlipidaemia, diabetes, cataract formation, peptic ulceration, osteopenia and aseptic necrosis of bone. (Table 1) The small molecule immunosuppressants include calcineurin inhibitors, such as cyclosporin, and antiproliferative drugs, such as sirolimus.
Small molecules
Calcineurin inhibitors
Since 
Mycophenolate mofetil
Since it was introduced into Australia in 1996 mycophenolate mofetil has largely replaced azathioprine in organ transplantation.
One advantage over azathioprine is that allopurinol can be used for gout prophylaxis without the need to reduce the dose of mycophenolate. Possibly because of its anti-B cell properties 2 mycophenolate seems particularly effective in severe forms of systemic lupus erythematosus. It is also gaining favour as a steroid-sparing drug in the maintenance phase of a number of immune disorders, particularly the vasculitides. 3 The main adverse effects are haematological and gastrointestinal. On higher doses a third of patients will develop
diarrhoea. An enteric-coated formulation of mycophenolate has been developed to try and reduce gastrointestinal adverse effects.
Therapeutic drug monitoring is available but not widely used.
Sirolimus and everolimus
These potent antiproliferative drugs have gained acceptance in renal transplantation as a strategy to minimise the use of calcineurin inhibitors in low immunological risk patients. 4 They have a decreased likelihood of causing hypertension and glucose intolerance. Although these drugs are associated with less nephrotoxicity than calcineurin antagonists, they potentiate A new monoclonal antibody, alemtuzumab, is directed against a surface molecule (CD54), which is widely distributed on lymphocytes, macrophages and dendritic cells, thereby causing severe and long-lasting depletion of these cell lines. As a result, the risk of serious infection is increased. The use of this antibody is cautiously making the transition from immunoprophylaxis in transplant recipients to a wider use in immune diseases. 8 Two monoclonal antibodies against tumour necrosis factor, infliximab and adalimumab, and etanercept which prevents tumour necrosis factor binding to its receptor, are licensed for use in rheumatoid arthritis. They are also being used in ankylosing spondylitis, psoriatic arthritis and inflammatory bowel disease. 9 Infusion reactions are common. Pooled intravenous immunoglobulin was introduced to restore immunocompetence to patients with congenital acquired immune deficiency syndrome. Paradoxically, the discovery of its ability to inhibit the production and binding of auto-and allo-antibodies means that it is now more widely used as an immunomodulatory drug in the treatment of debilitating autoimmune diseases and antibody-mediated allograft rejection. 10 The fact that immunoglobulin also provides passive immunity means that it is regarded as having a low risk of infectious complications compared to other immunosuppressants. Consequently, it has been used in many conditions without good supportive evidence of efficacy, so the Australian National Blood Authority guidelines now restrict its use. 11 Nevertheless, it is likely that immunoglobulin use will continue to rise as knowledge about its mechanisms of action accumulates.
Using immunosuppressants -strategies and protocols
Treatment protocols are designed to: Similarly, the disease being treated may be so pleomorphic that finding like populations to compare in trials becomes very difficult. For example, lupus nephritis has five distinct histological subtypes, each with their own prognosis.
Choosing immunosuppressive regimens
In order to make sound judgements when choosing a treatment protocol the clinician has to consider the clinical trial evidence and then decide: In choosing the dose and duration of immunosuppressive treatments, one must always weigh disease activity versus host fitness. For example, an elderly patient with perinuclear-ANCA positive microscopic polyangiitis, confined to the kidneys, with crescents in 10% of glomeruli, will not need as aggressive an approach as the same disease in a young patient, with 80% crescents, lung haemorrhage and mononeuritis multiplex.
Managing and monitoring patients taking immunosuppressants
Patients need to be under constant surveillance, usually by a partnership between the specialist and the general practitioner.
Frequency of visits depends on perceived level of risk, but typical parameters to monitor are summarised in Table 3 .
Patients may need prophylaxis against the adverse effects of their treatment ( 
Infection risk
Immunosuppression increases susceptibility to infections which can become life-threatening in a matter of hours. At first, common bacterial infections of wounds, chest or urine predominate, but after 1-2 months of therapy opportunistic infections emerge, particularly herpes viruses, pneumocystis pneumonia, fungi and atypical mycobacteria.
Vaccinations against influenza (injected) and pneumococcus are recommended in chronically immunosuppressed patients. 12
They are safe and reasonably effective when given in the stable maintenance phase. In general, live attenuated virus vaccines, such as varicella or measles, should not be given to immunosuppressed patients (or to close family contacts).
Cancer risk
In patients taking immunosuppressants, early cancers are often viral induced. They include lymphoproliferative disorders and cervical cancer. In the long term, nearly all common cancers are increased, but particularly skin cancers. After 20 years of immunoprophylaxis following renal transplant, 80% of Australian patients will have developed skin cancer. 
Conclusion
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Self-test questions
The following statements are either true or false (answers on page 115) 5. The risk of cervical cancer is increased in women taking immunosuppressant drugs.
6. Calcineurin inhibitors increase the risk of cardiovascular disease. Amphetamines were used as decongestants (Benzedrine) and
Dental notes
have been given to soldiers to increase energy and alertness.
They are still used for disorders like narcolepsy and attention deficit hyperactivity disorder, while cocaine is still in limited use as a topical anaesthetic. Even ecstasy has been used as an adjunct to psychotherapy in the USA.
Current patterns of use and abuse
The predominant amphetamine available during the 1980s was amphetamine sulphate. Introduction of legislative controls over the precursor materials has meant that in recent times over 90% of amphetamines seized have been methamphetamines.
Methamphetamines are produced by reduction of ephedrine or pseudoephedrine, found in decongestants and other household products, making them relatively simple drugs to produce.
Ecstasy is 3,4-methylenedioxymethamphetamine (MDMA) and
is mostly smuggled into Australia because of the lack of local expertise in production, although local production may be increasing. Cocaine is purified from a plant and is imported.
Formulations and cost
Amphetamines and ecstasy are commonly taken as tablets. The tablets can also be crushed and injected. Ecstasy costs between $30 and $50 a tablet.
There are several different kinds of methamphetamines available (see box). 'Speed' is methamphetamine powder, generally manufactured in Australia, and is usually low quality. 
Toxicokinetics and pharmacology
Oral amphetamines and MDMA have an onset of action within 30 minutes, with peak concentrations being reached in 1-3 hours.
The elimination half-life of these drugs ranges between 6 and 12 hours. Cocaine has an extremely rapid onset of action taken intravenously or inhaled, and between 30 and 60 minutes orally or intranasally. It has a short half-life of 30-90 minutes.
Psychostimulants cause an overall increase in the effects of monoamine neurotransmitters -noradrenaline, dopamine and serotonin -by increasing their release and blocking reuptake.
Amphetamines, MDMA and cocaine have the greatest effect on noradrenaline, serotonin and dopamine respectively. 3 Ecstasy primarily increases serotonergic activity while methamphetamine primarily increases adrenergic activity.
Cocaine also blocks fast sodium channels, causing local anaesthetic and pro-arrhythmic effects. 
Clinical presentations
Management
While some patients can just be observed, others will need management of specific complications.
Psychiatric complications
Psychiatric sequelae need to be managed in a calm, nonconfrontational manner, as for any agitated, potentially aggressive disorder. Either oral or intravenous sedation may be needed if further assessment is required and the patient is unco-operative. The primary aim is to ensure that the patient is not a risk to themselves or the staff. Benzodiazepines are preferred and have the added benefit of decreasing the likelihood of seizures. Antipsychotics such as haloperidol may be useful for patients with severe psychosis. 'Chemical sedation'
should only be given in a monitored environment where rapid intervention is possible in the event of respiratory compromise or hypotension.
Depressive symptoms can occur in the days following stimulant use. These may progress to overt depressive illness possibly warranting antidepressants. Suicidal ideation and suicide attempts may occur.
Cardiovascular complications
Hypertension associated with amphetamine and cocaine abuse is mostly transient and will not require specific management.
Benzodiazepines will generally provide adequate control of blood pressure in the agitated patient. Severe hypertension in the setting of possible neurovascular pathology may require vasodilators such as phentolamine or hydralazine.
If cardiac chest pain is suspected in someone who has taken cocaine it should be treated with aspirin, oxygen and nitrates. 
Serotonin syndrome
The diagnosis of serotonin toxicity is based on clinical findingsin particular clonus and hyperreflexia. 5 
Chronic sequelae
The most commonly repeated findings in studies of MDMA, methamphetamine and cocaine use have been problems in the area of learning and memory. There is both animal and human evidence of neurotoxicity, but the evidence as to whether this is reactive but reversible, or permanent and irreversible in humans is inconclusive.
New drugs
Some of the views expressed in the following notes on newly approved products should be regarded as tentative, as there may have been little experience in Australia of their safety or efficacy. However, the Editorial Executive Committee believes that comments made in good faith at an early stage may still be of value. As a result of fuller experience, initial comments may need to be modified. The Committee is prepared to do this. Before new drugs are prescribed, the Committee believes it is important that full information is obtained either from the manufacturer's approved product information, a drug information centre or some other appropriate source. Anaemia is common in patients with cancer particularly if they have been subjected to chemotherapy. In a placebo-controlled study of 349 patients with haematological malignancies, injecting epoetin beta subcutaneously three times a week for 16 weeks significantly reduced the need for blood transfusions. The patients' quality of life improved as their haemoglobin increased. 2 Another study of 241 patients with lymphoproliferative malignancies found that a once-weekly injection was as effective as three times a week. 3 In addition to treating chemotherapy-induced anaemia in non-myeloid malignancies, epoetin beta, like epoetin alfa, is approved for increasing the yield of autologous blood donations, for example when people donate their own blood before undergoing surgery. Epoetin beta is also approved for preventing anaemia in premature babies.
Deferasirox
As the packed cell volume increases the patient's blood pressure may rise. The risk of thrombosis may increase, particularly if there is a rise in platelet production. There is also a possibility that epoetin could stimulate tumour growth.
Iron studies and electrolytes should be regularly checked.
Most patients will require iron supplements. Neutralising anti-erythropoietin antibodies can develop. If this results in red cell aplasia treatment must stop.
The pain of subcutaneous injections of epoetin beta has been compared with that of epoetin alfa. In a small study patients were injected with both products for four weeks. Pain scores were significantly lower with epoetin beta. 4 Another study compared epoetin beta with buffered formulations of epoetin alfa, and saline, by giving 60 patients four simultaneous injections. Epoetin beta was more acceptable than epoetin alfa and some patients felt it was no more painful than the saline injection. 5 When indicated, epoetin beta will help to ameliorate the anaemia in most patients, but it may not improve long- There are different strains of the virus. This vaccine has been developed from the common G1 serotype (89-12 strain). The production process results in a live attenuated vaccine which can be given orally (on the inside of the cheek).
A phase II trial in Singapore involved 2464 babies aged 11-17 weeks. They were given three different concentrations of the vaccine or a placebo. The seroconversion rate was 75-86% after a month. A second dose was then given and this resulted in gastroenteritis was calculated to be 56-70%. 2 Another South American trial gave the vaccine to 31 673 babies at the ages of two and four months. Compared to a control group of 31 552 given a placebo, the vaccinated babies had a significantly reduced rate of severe gastroenteritis. In the cohort of 20 169 babies followed until they were one year old, nine vaccinees needed hospital admission, compared with 59 of the placebo group. The vaccine efficacy against severe gastroenteritis was 85%. 3 Adverse events which had a higher incidence with the vaccine than with placebo included irritability, flatulence, diarrhoea, reduced appetite and fever.
The vaccine can be given at the same time as other vaccines.
Although it can be given with oral polio vaccine, a gap of two weeks is suggested. As viral antigen is excreted in the stools there is a potential for transmission to other people.
A different rotavirus vaccine marketed in the USA was withdrawn in 1999 after it was associated with intussusception.
During the large South American study there were nine cases of intussusception following vaccination compared with 16 in the placebo group. Although the difference was not statistically significant, 56 deaths occurred after vaccination compared with 43 in the placebo group. 3 The vaccine is most likely to be of benefit in communities with a high incidence of severe rotavirus gastroenteritis.
Whether the multivalent vaccines under development will have greater effectiveness than this monovalent vaccine is currently uncertain.
manufacturer provided some data
Rotavirus vaccine (RotaTeq)
RotaTeq The viral surface proteins correspond to human rotavirus serotypes G1, G2, G3, G4 and P [8] . The P [8] antigen was included in the vaccine to potentially provide protection against other G-serotypes that may contain P [8] , for example serotype G9.
Safety and efficacy data for the vaccine were examined in a placebo-controlled trial of 68 038 babies. The vaccine was given to healthy infants with the first dose administered between 6 and 12 weeks of age then followed by two more doses at 4−10 week intervals. All infants had been immunised by the age of 32 weeks. Oral polio vaccine was not permitted to be given at the same time; however other childhood vaccines were allowed. 3 Serum antibody responses were measured in a sub-group of 189 babies 14 days after the third dose. The seroconversion rates for neutralising antibody (specific to serotypes contained in the vaccine) and antirotavirus IgA were higher in the vaccine group compared to the placebo group. However, it is not known if these antibodies are responsible for protection against rotavirus gastroenteritis.
The number of hospitalisations or emergency department visits due to infections with G1−4 and G9 serotypes was evaluated.
There were 383 cases in the 28 646 babies given the placebo compared to only 20 cases in the 28 488 babies given the vaccine. Depending on the serotype, the vaccine efficacy against hospitalisation or emergency department visits varied from 87.6% to 100%. Although these findings were statistically significant, the incidence of infections with some of the serotypes was very low. 3 In an efficacy sub-group analysis, vaccine efficacy against G1−4 and G9 rotavirus gastroenteritis of 'any severity' was evaluated during the first rotavirus season. There were 318 cases of infection among the 2305 babies in the placebo group compared to only 83 cases in the 2207 vaccinees. 3 There is an indication that the efficacy of this vaccine may decline in subsequent seasons since during the second rotavirus T T
